Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Karine Miquel-Hebert"'
Publikováno v:
EuroIntervention, 8(9), 1047-1051. EuroPCR
To assess the safety and performance of the XIENCE V everolimus-eluting stent (EES) versus the TAXUS paclitaxel-eluting stent (PES) in the treatment of patients with de novo coronary artery lesions after a five-year follow-up period. Second-generatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::395f6c18290f5fe996948b65f6bd13bf
https://doi.org/10.4244/eijv8i9a161
https://doi.org/10.4244/eijv8i9a161
Autor:
Susan Veldhof, Vasim Farooq, Krishnankutty Sudhir, Patrick W. Serruys, Cecile Dorange, Bernard Chevalier, Hector M. Garcia-Garcia, Karine Miquel-Hebert, Richard Rapoza, Roberto Diletti, Yoshinobu Onuma
Publikováno v:
American Heart Journal. 164:654-663
Background Currently, no data are available on the direct comparison between the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) and conventional metallic drug-eluting stents. Methods The ABSORB II study is a randomized, active
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74897882fc7f049bc32aafc5ef3ba86d
https://doi.org/10.1016/j.ahj.2012.08.010
https://doi.org/10.1016/j.ahj.2012.08.010
Autor:
Susan Veldhof, Vasim Farooq, Robert Whitbourn, Jacques J. Koolen, Robert-Jan van Geuns, Pieter C. Smits, Patrick W. Serruys, Jung Ho Heo, Evelyn Regar, Dougal McClean, Hector M. Garcia-Garcia, Karine Miquel-Hebert, Dariusz Dudek, Ian T Meredith, Bill D. Gogas, Roberto Diletti, Yoshinobu Onuma, Christos V. Bourantas, Xiaolin Li, Leif Thuesen, Bernard De Bruyne, Chrysafios Girasis, John A. Ormiston, Bernard Chevalier, Stephan Windecker
Publikováno v:
Diletti, R, Farooq, V, Girasis, C, Bourantas, C, Onuma, Y, Heo, J H, Gogas, B D, van Geuns, R-J, Regar, E, de Bruyne, B, Dudek, D, Thuesen, L, Chevalier, B, McClean, D, Windecker, S, Whitbourn, R J, Smits, P, Koolen, J, Meredith, I, Li, X, Miquel-Hebert, K, Veldhof, S, Garcia-Garcia, H M, Ormiston, J A & Serruys, P W 2013, ' Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement : does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial ', Heart, vol. 99, no. 2, pp. 98-105 . https://doi.org/10.1136/heartjnl-2012-302598
Heart, 99(2), 98-105. BMJ Publishing Group
Heart, 99(2), 98-105. BMJ Publishing Group
The long-term results after second generation everolimus eluting bioresorbable vascular scaffold (Absorb BVS) placement in small vessels are unknown. Therefore, we investigated the impact of vessel size on long-term outcomes, after Absorb BVS implant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc583b929cb58251e6daf77e68d94fa1
https://doi.org/10.1136/heartjnl-2012-302598
https://doi.org/10.1136/heartjnl-2012-302598
Autor:
Bill D. Gogas, Evelyn Regar, Vasim Farooq, Bernard De Bruyne, Jung Ho Heo, Hector M. Garcia-Garcia, Yoshinobu Onuma, Robert Whitbourn, Karine Miquel-Hebert, Jacques J. Koolen, Richard Rapoza, Cecile Dorange, Patrick W. Serruys, Robert-Jan van Geuns, Maria D. Radu, Leif Thuesen, Pieter C. Smits, John A. Ormiston, Salvatore Brugaletta, Dariusz Dudek, Bernard Chevalier, Dougal McClean, Stefan Windecker, Roberto Diletti
Publikováno v:
JACC: Cardiovascular Interventions. 5(6):656-665
Objectives This study sought to investigate in vivo the vascular response at the proximal and distal edges of the second-generation ABSORB everolimus-eluting bioresorbable vascular scaffold (BVS). Background The edge vascular response after implantat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abf70116669678f97cf11adc0ec782aa
Autor:
Dougal McClean, Pieter C. Smits, John A. Ormiston, Hector M. Garcia-Garcia, Leif Thuesen, Cecile Dorange, Stephan Windecker, Krishnankutty Sudhir, Susan Veldhof, Bernard De Bruyne, Karine Miquel Hebert, Robert Whitbourn, Jacques J. Koolen, Dariusz Dudek, Ian T Meredith, Yoshinobu Onuma, Robert-Jan van Geuns, Bernard Chevalier, Patrick W. Serruys
Publikováno v:
Journal of the American College of Cardiology. 58:1578-1588
Background—The first generation of the bioresorbable everolimus drug-eluting vascular scaffold showed signs of shrinkage at 6 months, which largely contributed to late luminal loss. Nevertheless, late luminal loss was less than that observed with b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0cc69664926bb67311e7940e9a7a22c
https://doi.org/10.1016/j.jacc.2011.05.050
https://doi.org/10.1016/j.jacc.2011.05.050
Publikováno v:
Catheterization and Cardiovascular Interventions. 77:1012-1017
This report describes the 4-year clinical outcomes of the SPIRIT II study, which randomized 300 patients to treatment with the XIENCE V everolimus-eluting stent (EES), or the TAXUS paclitaxel-eluting stent. At 4-year clinical follow-up, which was ava
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::903de4fabd2250a2ae1579eef5ddf034
https://doi.org/10.1002/ccd.22770
https://doi.org/10.1002/ccd.22770
Autor:
Karine Miquel-Hebert, Yoshinobu Onuma, Krishnankutty Sudhir, Patrick W. Serruys, Manejeh Yaqub, Alexandra J. Lansky, Peter Ruygrok, Lalitha Jonnavithula, Adriano Caixeta, Paul C. Gordon, James B. Hermiller, Gregg W. Stone, Xiaolu Su, Poornima Sood, Susan Veldhof
Publikováno v:
JACC: Cardiovascular Interventions. 3:1220-1228
Objectives: The purpose of this study was to investigate long-term 3-year clinical outcomes of an everolimus-eluting stent (EES) versus a paclitaxel-eluting stent (PES). Background Compared with PES, EES reduced target vessel failure and major advers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99c306e395b252b557f9d010ec123111
https://doi.org/10.1016/j.jcin.2010.07.017
https://doi.org/10.1016/j.jcin.2010.07.017
Autor:
Ian T. Meredith, Karine Miquel-Hebert, Evelyn Regar, Richard Rapoza, Pieter C. Smits, Stephan Windecker, Susan Veldhof, Hector M. Garcia-Garcia, Bernard De Bruyne, John A. Ormiston, Leif Thuesen, Yoshinobu Onuma, Dariusz Dudek, Dougal McClean, Cecile Dorange, Robert Whitbourn, Jacques J. Koolen, Bernard Chevalier, Patrick W. Serruys
Publikováno v:
Circulation, 122(22), 2301-2312. Lippincott Williams & Wilkins
Serruys, P W, Onuma, Y, Ormiston, J A, de Bruyne, B, Regar, E, Dudek, D, Thuesen, L, Smits, P C, Chevalier, B, McClean, D, Koolen, J, Windecker, S, Whitbourn, R, Meredith, I, Dorange, C, Veldhof, S, Miquel-Hebert, K, Rapoza, R & García-García, H M 2010, ' Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes ', Circulation, vol. 122, no. 22, pp. 2301-12 . https://doi.org/10.1161/CIRCULATIONAHA.110.970772
Serruys, P W, Onuma, Y, Ormiston, J A, de Bruyne, B, Regar, E, Dudek, D, Thuesen, L, Smits, P C, Chevalier, B, McClean, D, Koolen, J, Windecker, S, Whitbourn, R, Meredith, I, Dorange, C, Veldhof, S, Miquel-Hebert, K, Rapoza, R & García-García, H M 2010, ' Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes ', Circulation, vol. 122, no. 22, pp. 2301-12 . https://doi.org/10.1161/CIRCULATIONAHA.110.970772
Background— The first generation of the bioresorbable everolimus drug-eluting vascular scaffold showed signs of shrinkage at 6 months, which largely contributed to late luminal loss. Nevertheless, late luminal loss was less than that observed with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7466dfdcaa91f1e2ca0daceb5c51ff3
https://doi.org/10.1161/circulationaha.110.970772
https://doi.org/10.1161/circulationaha.110.970772
Autor:
Nico Bruining, Evelyn Regar, Patrick W. Serruys, Iddo Heller, Leif Thuesen, Yoshinobu Onuma, Ronald Hamers, Mark Webster, Karine Miquel-Hebert, Jos R.T.C. Roelandt, John A. Ormiston, D Dudek, Wai-Fung Cheong, Susan Veldhof, Ron T. van Domburg, Sebastiaan de Winter
Publikováno v:
JACC: Cardiovascular Interventions. 3(4):449-456
Objectives: The aim of this study was to investigate the feasibility of using quantitative differential echogenicity to monitor the in vivo absorption process of a drug-eluting poly-l-lactic-acid (...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b4b951fffc0f506c6a49252f0281ea4
Autor:
Peter Ruygrok, Gert Richardt, Susan Veldhof, Jörg Neuzner, Ashok Seth, Shuzou Tanimoto, Didier Carrié, Cecile Dorange, Jan J. Piek, Joachim Schofer, Yoshinobu Onuma, Patrick W. Serruys, Marcus Wiemer, Karine Miquel-Hebert, Leif Thuesen
Publikováno v:
Onuma, Y, Tanimoto, S, Ruygrok, P, Neuzner, J, Piek, J J, Seth, A, Schofer, J J, Richardt, G, Wiemer, M, Carrié, D, Thuesen, L, Dorange, C, Miquel-Hebert, K, Veldhof, S & Serruys, P W 2010, ' Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: Two-year angiographic and three-year clinical results from the SPIRIT II study ', Catheterization and Cardiovascular Interventions, vol. 76, no. 5, pp. 634-32 . https://doi.org/10.1002/ccd.22541
Catheterization and cardiovascular interventions, 76(5), 634-642. Wiley-Liss Inc.
Catheterization and Cardiovascular Interventions, 76(5), 634-642. Wiley-Liss Inc.
Catheterization and cardiovascular interventions, 76(5), 634-642. Wiley-Liss Inc.
Catheterization and Cardiovascular Interventions, 76(5), 634-642. Wiley-Liss Inc.
Udgivelsesdato: 2010-Mar-19 Background: Little is known about the impact of treatment with drug-eluting stents (DES) on calcified coronary lesions. This analysis sought to assess the safety and efficacy of the XIENCE V everolimus-eluting stent (EES)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ebe5ac3504c7d5dff55ea0e6b5ccfea
https://doi.org/10.1002/ccd.22541
https://doi.org/10.1002/ccd.22541